Stockreport

Mineralys: Big Pharma Threatens To Undermine Likely Hypertension Drug Approval [Seeking Alpha]

Mineralys Therapeutics, Inc.  (MLYS) 
PDF Lorundrostat demonstrated robust Phase 3 efficacy, but faces intense competition from AstraZeneca's baxdrostat, which may reach market six months earlier. MLYS holds [Read more]